Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort.

ABSTRACT:

Background

Tocilizumab and baricitinib are recommended treatment options for hospitalized COVID-19 patients requiring oxygen support. Literature about its efficacy and safety in a head-to-head comparison is scarce.

Methods

Hospitalized COVID-19 patients requiring oxygen were treated with tocilizumab or baricitinib additionally to dexamethasone. Tocilizumab was available from February till the 19th of September 2021 and baricitinib from 21st of September. The primary outcome was in-hospital mortality. Secondary outcome parameters were progression to mechanical ventilation (MV), length-of-stay (LOS) and potential side effects.

Results

159 patients (tocilizumab 68, baricitinib 91) with a mean age of 60.5 years, 64% male were included in the study. Tocilizumab patients we

SUBMITTER: Karolyi M 

PROVIDER: S-EPMC9461450 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature